AmpliPhi’s product development pathway
- Phase 1/2
- Phase 3
- Human therapeutic
- AmpliPhage-001: Lung Infections in Cystic Fibrosis (CF) Patients Caused by P. aeruginosa According to Global Data in April 2013, the market for CF therapeutics was $1.2 billion in 2012 and forecasted to grow to $4.6 billion in 2017, with 65% of this market in the United States. Our lead CF program targets P. aeruginosa, the most prevalent bacterial infection that leads to the highest mortality in patients with CF with approximately 440 deaths per year in the United States.
- AmpliPhage-002: Wound and Skin Infections Caused by S. aureus In conjunction with our CRADA with the USAMRMC and the WRAIR, we are developing a phage product that is intended to effectively treat acute and chronic wound and skin infections caused by S. aureus, including infections caused by methicillin-resistant (MRSA) strains of the same bacterium. MRSA infections are one of the most common causes of hospital-acquired (nosocomial) infections and Global Data estimates the MRSA market for infections alone was more than $2.7 billion in 2007. This market is forecast to grow to more than $3.5 billion by 2019.
- AmpliPhage-004: Gastrointestinal (GI) Infection Caused by C. difficile Infection (CDI) Clostridium difficile causes damaging infections, especially where normal bacteria have been disrupted by antibiotics. AmpliPhi is working to develop a bacteriophage therapeutic that will only target C.difficile, avoiding such effects.
- Acinetobacter baumannii is an increasing problem around the world and shows alarmingly high levels of antibiotic resistance. AmpliPhi scientists have identified a range of bacteriophages active against this infection.
The Company’s leading bacteriophage therapeutic programs target areas of significant unmet clinical need, and its proprietary technology has additional applications for the treatment of a broad range of serious infections.
Scroll over bars to the left for information.